<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035460</url>
  </required_header>
  <id_info>
    <org_study_id>952633</org_study_id>
    <nct_id>NCT04035460</nct_id>
  </id_info>
  <brief_title>A Pilot Study Comparing Oxygen Delivery Via Helmet Interface Versus High Flow Nasal Cannula</brief_title>
  <acronym>NOVA-pilot</acronym>
  <official_title>A Pilot Randomized Controlled Study of Non-invasive Oxygenation and Ventilation in Patients With Acute Hypoxemic Respiratory Failure (AHRF): A Comparison of Oxygen Delivery Via Helmet Interface Versus High Flow Nasal Cannula (HFNC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baystate Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baystate Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our main objective is to collect feasibility data on helmet NIPPV and other clinical elements&#xD;
      in to eventually prepare for a full scale randomized trial based on findings of this pilot&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute hypoxemia leading to respiratory failure are frequently supported by&#xD;
      endotracheal intubation and mechanical ventilation. Unfortunately an invasive approach to&#xD;
      support is associated with risks of lung injury, infection, need for heavy sedation, and&#xD;
      increased mortality. Non-invasive oxygen delivery, by mask (BiPAP or CPAP), high flow nasal&#xD;
      cannula or helmet interface, is better tolerated and reduces risks associated with invasive&#xD;
      mechanical ventilation. A growing body of medical literature and clinical experience suggests&#xD;
      that non-invasive oxygen delivery can prevent the need for endotracheal intubation in some&#xD;
      patients. This proposal will compare two different modes of non-invasive oxygen delivery:&#xD;
      helmet and high flow nasal cannula.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of intubation</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the rates of intubation for subjects with Acute Hypoxemic Respiratory Failure (AHRF) managed by non-invasive modalities High Flow Nasal Cannula (HFNC) and Helmet NIPPV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to intubation</measure>
    <time_frame>28 days</time_frame>
    <description>Hours and minutes from time of initiation of protocol until intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intubation-free days through day 28</measure>
    <time_frame>28 days</time_frame>
    <description>number of days from the time of randomization to day 28 after randomization on which the patient is not intubated and does not require invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ-failure-free days through day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Daily determination of presence or absence of Cardiovascular, Kidney, Liver, Central Nervous System, and Hematological Dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality prior to discharge from hospital (up to study day 90 whichever comes first)</measure>
    <time_frame>90 days</time_frame>
    <description>hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality to day 28</measure>
    <time_frame>28 days</time_frame>
    <description>hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU free-days to day 28</measure>
    <time_frame>28 days</time_frame>
    <description>days not in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>28 days</time_frame>
    <description>duration of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cross-over between groups</measure>
    <time_frame>28 days</time_frame>
    <description>The percentage of patients in each group crossed over to the alternative group or another form of noninvasive ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events other than failure of the noninvasive oxygenation device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator associated pneumonia, barotrauma</measure>
    <time_frame>28 days</time_frame>
    <description>Complications due to mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily dose of sedative medications (milligram)</measure>
    <time_frame>7 days</time_frame>
    <description>Assessment of Sedation medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest level of daily mobility through day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Activity level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of the devices</measure>
    <time_frame>28 days</time_frame>
    <description>Daily assessment with visual analog scale for comfort, range 0-5, with 0= no discomfort and 5=unable to tolerate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and reason for exclusion from enrollment to this trial of Helmet-NIPPV vs. HFNC</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Reasons for exclusion of patients meeting inclusion criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intubation in non-enrolled patients that meet inclusion and exclusion criteria</measure>
    <time_frame>28 days</time_frame>
    <description>Usual care comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Richmond Agitation and Sedation Scale (RASS)</measure>
    <time_frame>7 days</time_frame>
    <description>Highest daily RASS score. The scale range is -5 to +4 in integer increments, Where -5 is unarousable, 0 is alert and calm, and +4 is combative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confusion Assessment Method for the ICU (CAM-ICU)</measure>
    <time_frame>7 days</time_frame>
    <description>Daily assessment of presence or absence of delirium</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hypoxemic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Helmet oxygenation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to helmet NIPPV will receive noninvasive oxygenation and ventilation via a latex free helmet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Flow Nasal Oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxygen will be passed through a heated humidifier and applied continuously through large-bore nasal prongs</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Helmet</intervention_name>
    <description>The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.</description>
    <arm_group_label>Helmet oxygenation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Oxygen</intervention_name>
    <description>Large-bore nasal prongs through which oxygen is delivered at high flow rates</description>
    <arm_group_label>High Flow Nasal Oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. AHRF defined as:&#xD;
&#xD;
             A ratio of partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2)&#xD;
             between 100 - 250 mm Hg while breathing O2 from Venturi mask, or other delivery system&#xD;
             that allows quantification of FiO2 such as Mask-NIPPV or HFNC.&#xD;
&#xD;
             When no arterial blood gas (ABG) result available, use transcutaneous oxygen&#xD;
             saturation measurement (SpO2) to impute PaO2 (Appendix A.2 for Table of PaO2 / FiO2&#xD;
             imputed from SpO2 [Brown 2017]. If no oxygenation data prior to use of Mask-NIPPV or&#xD;
             HFNC are available, then P/F ratio 100 - 250 on Mask-NIPPV or HFNC meets this&#xD;
             criterion.&#xD;
&#xD;
          3. Respiratory rate (RR) â‰¥24 /min and/or subjective shortness of breath (Modified Borg&#xD;
             Dyspnea Scale â‰¥ 2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. P/F Ratio &lt; 100 (Severe ARDS) on quantifiable FiO2&#xD;
&#xD;
          2. More than 24 hours has elapsed since the patient met criteria for AHRF (Inclusion #2&#xD;
             and 3, above)&#xD;
&#xD;
          3. Urgent need for intubation&#xD;
&#xD;
             Criteria for intubation:&#xD;
&#xD;
             i. RR&gt;40 ii. Lack of improvement of respiratory muscle fatigue iii. Copious tracheal&#xD;
             secretions that require frequent suctioning iv. Acidosis with a potential Hydrogen&#xD;
             (pH) &lt;7.35 v. Acute hypercarbia (PaCO2 &gt; 45 mm Hg) vi. SpO2 &lt; 88% for more than 5&#xD;
             minutes despite FiO2 and non-invasive support vii. Respiratory or cardiac arrest viii.&#xD;
             Glasgow Coma Scale â‰¤ 8&#xD;
&#xD;
          4. Contraindication to HFNC, Helmet-NIPPV, or Mask-NIPPV&#xD;
&#xD;
          5. Upper airway obstruction, facial trauma&#xD;
&#xD;
          6. Copious secretions, airway bleeding, epistaxis or vomiting&#xD;
&#xD;
          7. Primary cause of respiratory failure is exacerbation of chronic obstructive pulmonary&#xD;
             disease (COPD) or asthma&#xD;
&#xD;
          8. Elevated intracranial pressure &gt;20 mm Hg&#xD;
&#xD;
          9. Home mechanical ventilation except for CPAP/BiPAP used solely for sleep disordered&#xD;
             breathing&#xD;
&#xD;
         10. Persistent hemodynamic instability (systolic blood pressure (SBP)&lt;90 or mean arterial&#xD;
             pressure (MAP)&lt;60 despite IV fluid resuscitation, or norepinephrine dose &gt; 0.1&#xD;
             mcg/kg/min or equivalent vasopressor dose)&#xD;
&#xD;
         11. Plan for procedure during which NIPPV or HFNC is contraindicated. Okay to enroll if&#xD;
             procedure is complete and AHRF persists within 24 hours.&#xD;
&#xD;
         12. Absence of airway protective gag reflex or cough&#xD;
&#xD;
         13. Tracheostomy&#xD;
&#xD;
         14. Lack of informed consent&#xD;
&#xD;
         15. Pregnancy&#xD;
&#xD;
         16. Actual body weight exceeding 1 kg per cm of height&#xD;
&#xD;
         17. Diffuse alveolar hemorrhage&#xD;
&#xD;
         18. Severe acute pancreatitis as etiology for hypoxemia&#xD;
&#xD;
         19. Recent upper gastrointestinal surgical anastomosis within the past 30 days&#xD;
&#xD;
         20. Enrollment in another clinical trial within the past 30 days&#xD;
&#xD;
         21. Unsuitable for non-invasive ventilation in the judgment of the treating MD&#xD;
&#xD;
         22. Decision to withhold life-sustaining treatment. Patients with Do-Not-Resuscitate (DNR)&#xD;
             or No Cardiopulmonary resuscitation (No CPR) order may be enrolled.&#xD;
&#xD;
         23. Do not intubate order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Tidswell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baystate Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baystate Medical Center</investigator_affiliation>
    <investigator_full_name>Mark Tidswell</investigator_full_name>
    <investigator_title>Associate Professor of Medicine and Surgery</investigator_title>
  </responsible_party>
  <keyword>non-invasive ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

